---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-22-000037"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:25:32.453626+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics reports Q3 2022 net loss of $11.9M; first patient dosed in WTX-124 Phase 1/1b trial

## Summary
- Net loss of $11.9M for Q3 2022 vs $13.8M in Q3 2021; cash and equivalents $140.5M as of Sept 30.
- First patient dosed in Phase 1/1b trial of WTX-124 (IL-2 INDUKINE) as monotherapy and in combination with KEYTRUDA; initial data expected Q4 2023.
- FDA cleared IND for WTX-330 (IL-12 conditionally activated molecule); Phase 1 study in immunotherapy-resistant tumors starting.
- Collaboration revenue from Jazz licensing agreement was $5.0M in Q3 2022 (none in prior year); R&D expenses $13.1M.
- Cash runway through at least Q2 2024, supported by existing cash, anticipated collaboration revenue, and term loan facility.

## SEC filing metadata
- accession: 0001785530-22-000037
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553022000037/0001785530-22-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553022000037/howl-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-22-000037
- JSON: https://secwatch.observer/filing/0001785530-22-000037.json
- Plain text: https://secwatch.observer/filing/0001785530-22-000037.txt

## Key facts
- Earnings Releases
  Werewolf Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $5.0 million.
  - Period: third quarter ended September 30, 2022
  - Revenue: $5.0 million
  - Result: reported results
  source text: sufficient to fund its operational expenses and capital expenditure requirements through at least the second quarter of 2024. • Collaboration revenue: Collaboration revenue was $5.0 million for the third quarter of 2022, compared to zero for the same period in 2021. Collaboration revenue is related to amortization of the $15.0 million upfront payment received in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000178553022000037/0001785530-22-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.